Advertisement

Advertisement

HK:2105 Stock Latest News

Laekna Starts First-Patient Phase I Trial of LAE118 and Deepens Vasque Bio Alliance

Company AnnouncementsLaekna Starts First-Patient Phase I Trial of LAE118 and Deepens Vasque Bio Alliance

Laekna Advances Obesity Drug LAE102 With Positive Phase I Data

PremiumCompany Announcements

Laekna Advances Obesity Drug LAE102 With Positive Phase I Data

1M ago

Laekna Signals Sharp Interim Turnaround on Licensing Revenue

PremiumCompany Announcements

Laekna Signals Sharp Interim Turnaround on Licensing Revenue

2M ago

Laekna’s Breast Cancer Drug LAE002 Wins NDA Acceptance in China

PremiumCompany Announcements

Laekna’s Breast Cancer Drug LAE002 Wins NDA Acceptance in China

2M ago

Laekna Schedules Board Meeting to Approve 2026 Interim Results

PremiumCompany Announcements

Laekna Schedules Board Meeting to Approve 2026 Interim Results

2M ago

Laekna Unveils HK$56 Million Insider-Backed Share Buyback Plan

PremiumCompany AnnouncementsLaekna Unveils HK$56 Million Insider-Backed Share Buyback Plan

3M ago

Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval

Company Announcements

Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval

3M ago

Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

Company Announcements

Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

4M ago

Laekna Shareholders Approve All Resolutions at 2026 AGM

PremiumCompany Announcements

Laekna Shareholders Approve All Resolutions at 2026 AGM

4M ago

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

PremiumCompany Announcements

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

5M ago

Laekna grants 15.3 million RSUs under 2024 share award scheme

PremiumCompany Announcements

Laekna grants 15.3 million RSUs under 2024 share award scheme

5M ago

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

PremiumCompany Announcements

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

6M ago

Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data

PremiumCompany AnnouncementsLaekna Advances Obesity Candidate LAE102 With Positive Phase I Data

7M ago

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

Company Announcements

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

7M ago

Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

Company Announcements

Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

7M ago

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

PremiumCompany Announcements

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

9M ago

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

PremiumCompany Announcements

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

9M ago

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

PremiumCompany Announcements

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

10M ago

Laekna Completes Enrollment for Phase III Breast Cancer Trial

PremiumCompany Announcements

Laekna Completes Enrollment for Phase III Breast Cancer Trial

10M ago

Laekna, Inc. Updates Nomination and Governance Committee

PremiumCompany AnnouncementsLaekna, Inc. Updates Nomination and Governance Committee

10M ago

Laekna, Inc. Announces Board of Directors and Committee Roles

Company Announcements

Laekna, Inc. Announces Board of Directors and Committee Roles

10M ago

Laekna, Inc. Updates Governance Committee Terms

Company Announcements

Laekna, Inc. Updates Governance Committee Terms

10M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >